I have a feeling the company obtained a high royalty rate in exchange for a low upfront. They hinted at this in the Discussion P.R."
bocxman: they may hinted about back loading the deal BUT i have a feeling thats not true and that the company is misleading us AGAIN.(they misled us in the past and they may do it again) dont forget the SEC is investigating bocx claims.
"If we knew more about the size and amount of milestone payments, as well as the royalty rate, we could talk intelligently about the deal....but at this point we're both just guessing when we say BOCX got the shaft and the next deal will be better"
what we know now is the amount of the upfront payment was only(250.000). The holy grail of cancer diagnosis and the only universal cancer test (as the Co want us to believe) got that small upfront!!!!!...as i said before i believe SOME of recaf hype but NOT all of it.
"Keep in mind the data has to REALLY HOLD UP if we are to become a general screening assay like HEP-C, TUBERCULOSIS, HIV, etc."
I dont think the internal data will hold up b/c the SEC is investigating bocx DATA accuracy claims. for me that put alot, i mean ALOOOT OF question marks ON THE 90+ ACCURACY claims.
thanks for your long msg bocxman and good luck for all.
